{"pub": "axios", "url": "https://axios.com/biogen-alzheimers-revival-skepticism-5072c2e0-c5b3-4516-ac09-14870a5b7a4b.html", "downloaded_at": "2019-10-23 09:36:00.173217+00:00", "title": "Biogen's Alzheimer's revival warrants skepticism", "language": "en", "text": "Data: Money.net; Chart: Axios Visuals\n\nBiogen was a shattered biotech company in March after it pulled the plugged on its new Alzheimer's drug, but it recaptured Wall Street's good graces by looking at its data again and deciding to shoot for FDA approval after all.\n\nReality check: Alzheimer's affects almost 6 million Americans, and those patients and their families have desperately sought an effective treatment. But independent experts have not reviewed Biogen's data, and the industry isn't exactly on good footing right now when it comes to being forthright about its data.", "description": "Many are skeptical of what this Alzheimer's drug could bring.", "authors": [], "top_image": "https://images.axios.com/g86FwPBsUKtUB9-JSAdZ-yW0_3s=/0x0:1600x900/1920x1080/2019/10/22/1571776704408.png", "published_at": "2019-10-23"}